|
1
|
Soriano A, Honore PM, Puerta-Alcalde P,
Garcia-Vidal C, Pagotto A, Gonçalves-Bradley DC and Verweij PE:
Invasive candidiasis: Current clinical challenges and unmet needs
in adult populations. J Antimicrob Chemother. 78:1569–1585.
2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kullberg BJ and Arendrup MC: Invasive
candidiasis. N Engl J Med. 373:1445–1456. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Paramythiotou E, Frantzeskaki F, Flevari
A, Armaganidis A and Dimopoulos G: Invasive fungal infections in
the ICU: How to approach, how to treat. Molecules. 19:1085–1119.
2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gonzalez-Lara MF and Ostrosky-Zeichner L:
Invasive Candidiasis. Semin Respir Crit Care Med. 41:3–12.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Van de Veerdonk FL, Kullberg BJ and Netea
MG: Pathogenesis of invasive candidiasis. Curr Opin Crit Care.
16:453–459. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Thomas-Rüddel DO, Schlattmann P, Pletz M,
Kurzai O and Bloos F: Risk factors for invasive candida infection
in critically Ill patients: A systematic review and meta-analysis.
Chest. 161:345–355. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Barantsevich N and Barantsevich E:
Diagnosis and treatment of invasive candidiasis. Antibiotics
(Basel). 11(718)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Oliva A, De Rosa FG, Mikulska M, Pea F,
Sanguinetti M, Tascini C and Venditti M: Invasive Candida
infection: Epidemiology, clinical and therapeutic aspects of an
evolving disease and the role of rezafungin. Expert Rev Anti Infect
Ther. 21:957–975. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Clancy CJ and Nguyen MH: Diagnosing
invasive candidiasis. J Clin Microbiol. 56:e01909–17.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ellepola AN and Morrison CJ: Laboratory
diagnosis of invasive candidiasis. J Microbiol. 43:65–84.
2005.PubMed/NCBI
|
|
11
|
Ylipalosaari P, Ala-Kokko TI, Koskenkari
J, Laurila JJ, Ämmälä S and Syrjälä H: Use and outcome of empiric
echinocandins in critically ill patients. Acta Anaesthesiol Scand.
65:944–951. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ben-Ami R: Treatment of invasive
candidiasis: A narrative review. J Fungi (Basel).
4(97)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
De Oliveira Santos GC, Vasconcelos CC,
Lopes AJO, de Sousa Cartágenes MDS, Filho AKDB, do Nascimento FRF,
Ramos RM, Pires ERRB, de Andrade MS, Rocha FMG and de Andrade
Monteiro C: Candida infections and therapeutic strategies:
Mechanisms of action for traditional and alternative agents. Front
Microbiol. 9(1351)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mermel LA, Allon M, Bouza E, Craven DE,
Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ and Warren
DK: Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 Update by the
Infectious Diseases Society of America. Clin Infect Dis. 49:1–45.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Peçanha-Pietrobom PM and Colombo AL: Mind
the gaps: Challenges in the clinical management of invasive
candidiasis in critically ill patients. Curr Opin Infect Dis.
33:441–448. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mehta Y: Challenges in the diagnosis and
treatment of invasive candidiasis in India. Int J Crit Care Emerg
Med. 10(165)2024.
|
|
17
|
Logan C, Martin-Loeches I and Bicanic T:
Invasive candidiasis in critical care: Challenges and future
directions. Intensive Care Med. 46:2001–2014. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hankovszky P, Társy D, Öveges N and Molnár
Z: Invasive candida infections in the ICU: Diagnosis and therapy. J
Crit Care Med (Targu Mures). 1:129–139. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Aldardeer NF, Albar H, Al-Attas M, Eldali
A, Qutub M, Hassanien A and Alraddadi B: Antifungal resistance in
patients with Candidaemia: A retrospective cohort study. BMC Infect
Dis. 20(55)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mei-Sheng Riley M: Invasive fungal
infections among immunocompromised patients in critical care
settings: Infection prevention risk mitigation. Crit Care Nurs Clin
North Am. 33:395–405. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Delaloye J and Calandra T: Invasive
candidiasis as a cause of sepsis in the critically ill patient.
Virulence. 5:161–169. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Almirante B, Rodríguez D, Park BJ,
Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats
J, Gimenez M, et al: Epidemiology and predictors of mortality in
cases of Candida bloodstream infection: Results from
population-based surveillance, barcelona, Spain, from 2002 to 2003.
J Clin Microbiol. 43:1829–1835. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bellmann R and Smuszkiewicz P:
Pharmacokinetics of antifungal drugs: Practical implications for
optimized treatment of patients. Infection. 45:737–779.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pfaller MA: Application of
Culture-independent rapid diagnostic tests in the management of
invasive candidiasis and cryptococcosis. J Fungi (Basel).
1:217–251. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bassetti M, Mikulska M and Viscoli C:
Bench-to-bedside review: Therapeutic management of invasive
candidiasis in the intensive care unit. Crit Care.
14(244)2010.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Lepak AJ and Andes DR: Antifungal
pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect
Med. 5(a019653)2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ademe M: Immunomodulation for the
treatment of fungal infections: Opportunities and challenges. Front
Cell Infect Microbiol. 10(469)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Alhamad H, Abu-Farha R, Albahar F, Jaber
D, Abu Assab M, Edaily SM and Donyai P: The impact of antifungal
stewardship on clinical and performance measures: A global
systematic review. Trop Med Infect Dis. 9(8)2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pappas PG, Kauffman CA, Andes DR, Clancy
CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez
JA, Walsh TJ, et al: Clinical practice guideline for the management
of candidiasis: 2016 update by the infectious diseases society of
America. Clin Infect Dis. 62:e1–e50. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kumar NR, Balraj TA, Kempegowda SN and
Prashant A: Multidrug-resistant sepsis: A critical healthcare
challenge. Antibiotics (Basel). 13(46)2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hurley JC: Trends in ICU mortality and
underlying risk over three decades among mechanically ventilated
patients. A group level analysis of cohorts from infection
prevention studies. Ann Intensive Care. 13(62)2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mayer LM, Strich JR, Kadri SS, Lionakis
MS, Evans NG, Prevots DR and Ricotta EE: Machine learning in
infectious disease for risk factor identification and hypothesis
generation: Proof of concept using invasive candidiasis. Open Forum
Infect. 9(ofac401)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Noppè E, Eloff JRP, Keane S and
Martin-Loeches I: A Narrative review of invasive candidiasis in the
intensive care unit. Ther Adv Pulm Crit Care Med.
19(29768675241304684)2024.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Baltogianni M, Giapros V and Dermitzaki N:
Recent challenges in diagnosis and treatment of invasive
candidiasis in neonates. Children (Basel). 11(1207)2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Pham D, Sivalingam V, Tang HM, Montgomery
JM, Chen S and Halliday CL: Molecular diagnostics for invasive
fungal diseases: Current and future approaches. J Fungi (Basel).
10(447)2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Pappas PG, Lionakis MS, Arendrup MC,
Ostrosky-Zeichner L and Kullberg BJ: Invasive candidiasis. Nat Rev
Dis Primers. 4(18026)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yi WM, Schoeppler KE, Jaeger J, Mueller
SW, MacLaren R, Fish DN and Kiser TH: Voriconazole and posaconazole
therapeutic drug monitoring: A retrospective study. Ann Clin
Microbiol Antimicrob. 16(60)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
König C, Göpfert M, Kluge S and Wichmann
D: Posaconazole exposure in critically ill ICU patients: A need for
action. Infection. 51:1767–1772. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sigera LSM and Denning DW: Flucytosine and
its clinical usage. Ther Adv Infect Dis.
10(20499361231161387)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Baracaldo-Santamaría D, Cala-Garcia JD,
Medina-Rincón GJ, Rojas-Rodriguez LC and Calderon-Ospina CA:
Therapeutic drug monitoring of antifungal agents in critically Ill
patients: Is there a need for dose optimisation? Antibiotics
(Basel). 11(645)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jiang L and Lin Z: Voriconazole: A review
of adjustment programs guided by therapeutic drug monitoring. Front
Pharmacol. 15(1439586)2024.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sendid B, Poirot JL, Tabouret M, Bonnin A,
Caillot D, Camus D and Poulain D: Combined detection of mannanaemia
and antimannan antibodies as a strategy for the diagnosis of
systemic infection caused by pathogenic Candida species. J Med
Microbiol. 51:433–442. 2002.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Prella M, Bille J, Pugnale M, Duvoisin B,
Cavassini M, Calandra T and Marchetti O: Early diagnosis of
invasive candidiasis with mannan antigenemia and antimannan
antibodies. Diagn Microbiol Infect Dis. 51:95–101. 2005.PubMed/NCBI View Article : Google Scholar
|
